Sun Pharma signs global licensing pact with CSIR-IICT for patents

Topics Sun Pharma | Dilip Shanghvi | BSE

Sun Pharmaceutical Industries on Wednesday said it has entered into a global licensing pact with Hyderabad-based CSIR Indian Institute of Chemical Technology (CSIR-IICT) for ceratin patents related to the company's specialty focus areas.

The specialty focus areas include segments like dermatology, ophthalmology and oncology.

"Under the terms of the licence agreement, Sun Pharma gets exclusive global licence for the said patents and any other future patents covered in the agreement," the company said in a statement.

Sun Pharma will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totalling up to Rs 240 crore plus royalties on net sales from commercialisation of the products developed using these patents, it added.

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications.

The company will be responsible for development, regulatory filings, manufacturing and commercialisation of these potential products, the statement said.

"This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline," Sun Pharma MD Dilip Shanghvi said.

The drug firm is making earnest efforts to bring innovations from Indian research institutes to the market to address the unmet needs of patients globally. The collaboration with CSIR-IICT is a step in this direction, he added.

This agreement will facilitate addition of pre-clinical candidates to Sun Pharma's global specialty pipeline, the statement said.

"A successful clinical development of these potential compounds may enable Sun Pharma to commercialise pharmaceutical products for various therapeutic indications over the long term," it added.

Shares of Sun Pharmaceutical Industries were trading at Rs 417.15 per scrip on the BSE, down 4.66 per cent from the previous close.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel